- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01029249
Examining the Incidence of Oral Human Papillomavirus (HPV) Shedding and Oral Warts After Beginning HAART in HIV-Infected Adults
Oral HPV Shedding and Oral Warts After Initiation of Antiretroviral Therapy
Přehled studie
Postavení
Podmínky
Detailní popis
Oral HPV infection occurs at a higher rate among HIV-infected people than among the general population. Recent research in the United States and Europe has also found that HIV-infected people have a higher risk of oral and oropharyngeal squamous cell cancer than HIV-uninfected people. In one study, it was found that HPV seropositivity was associated with an increased risk of squamous cell carcinoma of the oropharynx (SCCOP). In addition to SCCOP, another HPV-related health concern is oral warts, a condition for which there is no effective treatment. Even after beginning treatment with highly active antiretroviral therapy (HAART), active HPV replication in the mouth and oropharynx may persist in HIV-infected people, leading to an increased risk of SCCOP and oral warts. The purpose of this study is to evaluate the frequency of oral HPV DNA shedding and oral warts in HIV-infected people prior to HAART initiation and at regular time points after HAART initiation.
ACTG A5257 is a study that is comparing the effectiveness of three non-nucleoside reverse transcriptase inhibitor (NNRTI)-sparing HAART regimens in treatment-naïve participants. This study will enroll participants from the ACTG A5257 study. Participants will attend a baseline study visit at the same time as their ACTG A5257 baseline study visit. At baseline and at Week 4, 16, 24, and 48 study visits, participants will undergo an examination of their mouth, throat wash and saliva collection, and behavioral questionnaires. A blood collection will also occur at Week 24.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
-
San Juan, Portoriko, 00931
- Puerto Rico-AIDS CRS (5401)
-
-
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35294-2050
- Alabama Therapeutics CRS (5801)
-
-
California
-
Los Angeles, California, Spojené státy, 90095
- UCLA CARE Center CRS (601)
-
Los Angeles, California, Spojené státy, 90033
- University of Southern California CRS (1201)
-
Palo Alto, California, Spojené státy, 94304
- Stanford
-
San Diego, California, Spojené státy, 92103
- Ucsd, Avrc Crs (701)
-
San Francisco, California, Spojené státy, 94110
- University of California San Francisco AIDS CRS (801)
-
-
Florida
-
Miami, Florida, Spojené státy, 33139
- University of Miami AIDS CRS (901)
-
-
Georgia
-
Atlanta, Georgia, Spojené státy, 30308
- The Ponce de Leon Ctr. CRS (5802)
-
-
Illinois
-
Chicago, Illinois, Spojené státy, 60611
- Northwestern University CRS (2701)
-
Chicago, Illinois, Spojené státy, 60612
- Rush University Medical Center (2702)
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- IHV Baltimore Treatment CRS (4651)
-
Boston, Maryland, Spojené státy, 02215
- Beth Israel Deaconess Medical Center ACTG CRS (103)
-
-
Massachusetts
-
Boston, Massachusetts, Spojené státy, 02114
- Massachusetts General Hospital ACTG CRS (101)
-
-
Michigan
-
Detroit, Michigan, Spojené státy, 48202
- Henry Ford Hosp. CRS (31472)
-
-
Missouri
-
St. Louis, Missouri, Spojené státy, 63110
- Washington University CRS (2101)
-
-
New Jersey
-
Camden, New Jersey, Spojené státy, 08103
- Cooper Univ. Hosp. CRS (31476)
-
Newark, New Jersey, Spojené státy, 07103
- New Jersey Medical School- Adult Clinical Research Ctr. CRS
-
-
New York
-
New York, New York, Spojené státy, 10011
- Cornell CRS (7804)
-
New York, New York, Spojené státy, 10032
- HIV Prevention and Treatment
-
Rochester, New York, Spojené státy, 14642
- University of Rochester ACTG CRS (1101)
-
Rochester, New York, Spojené státy, 14607
- AIDS Care CRS (1108)
-
-
North Carolina
-
Chapel Hill, North Carolina, Spojené státy, 27514
- University of North Carolina AIDS CRS
-
Durham, North Carolina, Spojené státy, 27710
- Duke Univ. Med. Ctr. Adult CRS (1601)
-
Greensboro, North Carolina, Spojené státy, 27401
- Moses H. Cone Memorial Hosp. CRS
-
-
Ohio
-
Cincinnati, Ohio, Spojené státy, 45267
- University of Cincinnati CRS
-
Cleveland, Ohio, Spojené státy, 44106
- Case CRS (2501)
-
Cleveland, Ohio, Spojené státy, 44109
- MetroHealth CRS (2503)
-
Colombus, Ohio, Spojené státy, 43210
- The Ohio State University AIDS CRS (2301)
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Spojené státy, 19104
- Hospital of the University of Pennsylvania CRS (6201)
-
-
Rhode Island
-
Providence, Rhode Island, Spojené státy, 02906
- The Miriam Hospital ACTG CRS (2951)
-
-
Tennessee
-
Nashville, Tennessee, Spojené státy, 37232
- Vanderbilt Therapeutics CRS (3652)
-
-
Texas
-
Houston, Texas, Spojené státy, 77030
- Houston AIDS Research Team CRS (31473)
-
-
Virginia
-
Richmond, Virginia, Spojené státy, 23219
- Virginia Commonwealth Univ. Medical Ctr. CRS (31475)
-
-
Washington
-
Seattle, Washington, Spojené státy, 98104
- University of Washington AIDS CRS (1401)
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Meet inclusion criteria for and be enrolled in ACTG A5257
- Ability and willingness of participant or legal guardian/representative to provide informed consent
Exclusion Criteria:
- Co-enrollment in A5260s
- Has begun receiving HAART as part of the A5257 study
- Has ever received an HPV vaccine or plans to receive an HPV vaccine in the 6 months after study entry
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Kohorta
- Časové perspektivy: Budoucí
Kohorty a intervence
Skupina / kohorta |
---|
ACTG A5257 participants
Participants in this study will also be enrolled in ACTG A5257.
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Type-specific oral HPV DNA shedding (presence versus absence)
Časové okno: Measured at baseline (measured at pre-entry and entry into A5257) and at Weeks 16 and 24
|
Measured at baseline (measured at pre-entry and entry into A5257) and at Weeks 16 and 24
|
Persistence of same type HPV DNA shedding from pre-entry/baseline visits to Week 16 and 24 visits
Časové okno: Measured at Weeks 16 and 24
|
Measured at Weeks 16 and 24
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Clinical diagnosis (presence versus absence) of oral warts
Časové okno: Measured at Weeks 16 and 24
|
Measured at Weeks 16 and 24
|
HPV shedding at one of the pre-HAART visits
Časové okno: Measured at one of the pre-entry visits
|
Measured at one of the pre-entry visits
|
CD4 count change (compared to baseline)
Časové okno: Measured at Weeks 4, 16, and 24
|
Measured at Weeks 4, 16, and 24
|
Plasma HIV-1 RNA suppression
Časové okno: Measured at Weeks 4, 16, and 24
|
Measured at Weeks 4, 16, and 24
|
Quantitative changes in HPV DNA in oral specimens obtained from participants who have the same HPV subtypes at one of the two pre-HAART visits as well as at Week 16 or 24
Časové okno: Measured at Weeks 16 or 24
|
Measured at Weeks 16 or 24
|
Clinical diagnosis (presence versus absence) or oral warts measured by a visual exam
Časové okno: Measured at baseline and Weeks 16, 24, and 48
|
Measured at baseline and Weeks 16, 24, and 48
|
Number of oral sex partners in the last month
Časové okno: Measured at baseline and Weeks 24 and 48
|
Measured at baseline and Weeks 24 and 48
|
Number of oral sex partners in the last 6 months
Časové okno: Measured at baseline and Weeks 24 and 48
|
Measured at baseline and Weeks 24 and 48
|
Absolute CD8 count (obtained from A5257 study data)
Časové okno: Measured at Weeks 0 and 24 in the A5257 study
|
Measured at Weeks 0 and 24 in the A5257 study
|
Absolute CD4 count (obtained from A5257 study data)
Časové okno: Measured at Weeks 0, 24, and 48 in the A5257 study
|
Measured at Weeks 0, 24, and 48 in the A5257 study
|
Percentage and absolute number of CD4 cells that are interleukin (IL)-2+/interferon (IFN)+ or transforming growth factor (TGF)+ after HPV peptide stimulation measured from peripheral blood mononuclear cells (PBMCs)
Časové okno: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Percentage and absolute number of CD8 cells that are IFN, tumor necrosis factor (TNF), TGF+, or CD107+ after HPV peptide stimulation measured from PBMCs
Časové okno: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Percentage and absolute number of CD4 cells that are regulatory T cells (CD4+/CD25+/CD127low) measured from PBMCs
Časové okno: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Percentage of CD4 cells and CD8 cells that express CD38 and HLA-DR
Časové okno: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Persistence of HPV DNA of a specific type in throat wash specimens over the time course of the study
Časové okno: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Salivary total lgA and anti-HPV lgA and S-lgA titers
Časové okno: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Serum total anti-HPV lgG titers
Časové okno: Measured during the A5272 study or obtained from stored specimens
|
Measured during the A5272 study or obtained from stored specimens
|
Spolupracovníci a vyšetřovatelé
Sponzor
Spolupracovníci
Vyšetřovatelé
- Studijní židle: Caroline Shiboski, DDS, MPH, PhD, Department of Orofacial Sciences, UCSF AIDS OHARA
- Studijní židle: Mark A. Jacobson, MD, UCSF AIDS OHARA, Positive Health Program, San Francisco General Hospital
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- ACTG A5272
- 1U01AI068636 (Grant/smlouva NIH USA)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na HIV infekce
-
Ottawa Hospital Research InstitutePfizerDokončenoHIV infekce | HIV-1 infekce | Mycobacterium Avium Complex (MAC)Kanada
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...AbbottDokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-IntracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
National Institute of Allergy and Infectious Diseases...DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy, Tanzanie
-
AbbottDokončenoHIV infekce | Intracelulární infekce Mycobacterium AviumSpojené státy, Portoriko
-
AbbottNational Cancer Institute (NCI)DokončenoHIV infekce | Infekce Mycobacterium Avium-intracellulareSpojené státy
-
Aaron Diamond AIDS Research CenterDokončenoHIV infekce | Infekce Mycobacterium Avium-Intracellulare | Tuberkulóza, infekce MycobacteriumSpojené státy